Literature DB >> 1155069

Plasma concentrations of phenobarbital in the treatment of seizures in newborns.

B Jalling.   

Abstract

The plasma concentration of phenobarbital given as anticonvulsive treatment in the newborn period has been followed in 18 infants. With constant daily doses, the drug accummulated for at least 5 days. After intramuscular injection of a single dose, 90% of the peak concentration was reached within 4 hours in 8 of the 10 infants. The peak concentration (in mug/ml) approximately equalled 1.3 x the dose (in mg/kg). Absorption after oral administration was less reliable. In 12 of the infants the clinical course allowed attempts to evaluate the anticonvulsive effect of phenobarbital. In 4 cases the convulsions continued. In those 8 infants where phenobarbital seemed to be effective, the approximate range of phenobarbital concentration when convulsions ceased was 12-30 mug/ml. Phenobarbital half-life ranged between 59 and 182 hours. In some infants the rate of phenobarbital disappearance from the plasma varied considerably from day to day. The pathological conditions causing seizures probably influence the distribution, metabolism and excretion of the drug. For the often seriously ill infants with convulsions it is therefore difficult to construct rational maintenance dose schedules, and optimal dosage must be based on repeated determinations of the plasma concentration.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1155069     DOI: 10.1111/j.1651-2227.1975.tb03873.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  12 in total

Review 1.  Pharmacotherapy for Seizures in Neonates with Hypoxic Ischemic Encephalopathy.

Authors:  Elissa Yozawitz; Arthur Stacey; Ronit M Pressler
Journal:  Paediatr Drugs       Date:  2017-12       Impact factor: 3.022

Review 2.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

3.  Maturation of caffeine elimination in infancy.

Authors:  J V Aranda; J M Collinge; R Zinman; G Watters
Journal:  Arch Dis Child       Date:  1979-12       Impact factor: 3.791

4.  Anticonvulsants in the newborn period.

Authors:  N Buchanan
Journal:  Indian J Pediatr       Date:  1985 Sep-Oct       Impact factor: 1.967

5.  Pharmacokinetics of phenobarbital in childhood.

Authors:  G Heimann; E Gladtke
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

Review 6.  Therapeutic drug monitoring of anticonvulsants. State of the art.

Authors:  I A Choonara; A Rane
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

7.  Pharmacokinetics and clinical effect of phenobarbital in children with severe falciparum malaria and convulsions.

Authors:  Gilbert O Kokwaro; Bernhards R Ogutu; Simon N Muchohi; Godfrey O Otieno; Charles R J C Newton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

9.  Brain-orientated intensive care treatment in severe neonatal asphyxia. Effects of phenobarbitone protection.

Authors:  N W Svenningsen; G Blennow; M Lindroth; P O Gäddlin; H Ahlström
Journal:  Arch Dis Child       Date:  1982-03       Impact factor: 3.791

10.  Phenobarbitone dosage in neonatal convulsions.

Authors:  R A Ouvrier; R Goldsmith
Journal:  Arch Dis Child       Date:  1982-09       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.